JP2020500875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500875A5 JP2020500875A5 JP2019529533A JP2019529533A JP2020500875A5 JP 2020500875 A5 JP2020500875 A5 JP 2020500875A5 JP 2019529533 A JP2019529533 A JP 2019529533A JP 2019529533 A JP2019529533 A JP 2019529533A JP 2020500875 A5 JP2020500875 A5 JP 2020500875A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrido
- hexahydro
- dimethoxy
- isobutyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 isoquinolin-2-yl Chemical group 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- 208000028017 Psychotic disease Diseases 0.000 claims description 5
- 230000000155 isotopic effect Effects 0.000 claims description 5
- 208000022610 schizoaffective disease Diseases 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 2
- GEJDGVNQKABXKG-CFKGEZKQSA-N [(2r,3r,11br)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl] (2s)-2-amino-3-methylbutanoate Chemical compound C1CN2C[C@@H](CC(C)C)[C@H](OC(=O)[C@@H](N)C(C)C)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 GEJDGVNQKABXKG-CFKGEZKQSA-N 0.000 claims description 2
- 231100000871 behavioral problem Toxicity 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 14
- HPZNBNITYLLYBM-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.NC(C(=O)ON1CC2=CC=CC=C2C=C1)C(C)C Chemical compound CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.NC(C(=O)ON1CC2=CC=CC=C2C=C1)C(C)C HPZNBNITYLLYBM-UHFFFAOYSA-N 0.000 claims 2
- 239000007963 capsule composition Substances 0.000 claims 1
- 239000007916 tablet composition Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022189060A JP2023015405A (ja) | 2016-12-02 | 2022-11-28 | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| JP2025010365A JP2025071099A (ja) | 2016-12-02 | 2025-01-24 | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662429652P | 2016-12-02 | 2016-12-02 | |
| US62/429,652 | 2016-12-02 | ||
| PCT/US2017/064196 WO2018102673A1 (en) | 2016-12-02 | 2017-12-01 | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022189060A Division JP2023015405A (ja) | 2016-12-02 | 2022-11-28 | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500875A JP2020500875A (ja) | 2020-01-16 |
| JP2020500875A5 true JP2020500875A5 (cg-RX-API-DMAC7.html) | 2021-01-21 |
| JPWO2018102673A5 JPWO2018102673A5 (cg-RX-API-DMAC7.html) | 2022-04-08 |
Family
ID=60703209
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529533A Withdrawn JP2020500875A (ja) | 2016-12-02 | 2017-12-01 | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| JP2022189060A Withdrawn JP2023015405A (ja) | 2016-12-02 | 2022-11-28 | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| JP2025010365A Pending JP2025071099A (ja) | 2016-12-02 | 2025-01-24 | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022189060A Withdrawn JP2023015405A (ja) | 2016-12-02 | 2022-11-28 | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| JP2025010365A Pending JP2025071099A (ja) | 2016-12-02 | 2025-01-24 | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200078352A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4400171A3 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2020500875A (cg-RX-API-DMAC7.html) |
| TW (3) | TW201827051A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018102673A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20240304T1 (hr) | 2015-10-30 | 2024-05-10 | Neurocrine Biosciences, Inc. | Soli valbenazin dihidroklorida i njihovi polimorfi |
| LT3394057T (lt) | 2015-12-23 | 2022-06-27 | Neurocrine Biosciences, Inc. | Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą) |
| KR20190108146A (ko) | 2017-01-27 | 2019-09-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| IL309802A (en) | 2017-09-21 | 2024-02-01 | Neurocrine Biosciences Inc | High dose valbenazine formulation and related preparations, methods and kits |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| EP3733666B1 (en) | 2017-12-26 | 2022-09-21 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof |
| WO2019241555A1 (en) * | 2018-06-14 | 2019-12-19 | Neurocrine Biosciences, Inc. | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
| CN110818705A (zh) * | 2018-08-14 | 2020-02-21 | 苏州鹏旭医药科技有限公司 | 缬苯那嗪的盐型和相应晶型与其制备方法 |
| JOP20200336A1 (ar) | 2018-08-15 | 2020-12-22 | Neurocrine Biosciences Inc | طرق إعطاء مثبطات vmat2 معينة |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| CN112933055B (zh) * | 2021-03-23 | 2023-01-13 | 安徽九华华源药业有限公司 | 帕利哌酮胃滞留片及其制备方法 |
| JP2024524324A (ja) * | 2021-06-30 | 2024-07-05 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症のアドオン処置において使用するためのバルベナジン |
| TW202322816A (zh) | 2021-08-20 | 2023-06-16 | 美商紐羅克里生物科學有限公司 | 篩選 vmat2 抑制劑之方法 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| DE69632684T2 (de) | 1995-06-27 | 2005-06-09 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| KR100353304B1 (ko) | 1996-10-01 | 2002-09-30 | 에스알아이 인터내셔널 | 맛이 차폐된 마이크로캡슐 조성물 및 이것의 제조 방법 |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| EP1313473A2 (en) | 2000-08-30 | 2003-05-28 | Pfizer Products Inc. | Sustained release formulations for growth hormone secretagogues |
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| EP1855677B1 (en) * | 2005-08-06 | 2008-12-03 | Cambridge Laboratories (Ireland) Limited | 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
| US8039627B2 (en) | 2006-11-08 | 2011-10-18 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| WO2011019956A2 (en) | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| HUE038158T2 (hu) | 2008-09-18 | 2018-09-28 | Auspex Pharmaceuticals Inc | Deuterizált benzokinolizin származékok vezikuláris monoamin transzporter-2 inhibitorként |
| EP3006024B1 (en) * | 2009-01-20 | 2019-03-20 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Benzoic acid or salts thereof to enhance the activity of a neuropharmaceutical |
| IT1399315B1 (it) * | 2010-04-08 | 2013-04-16 | Cappelli | Procedimento per disporre su una qualsiasi superficie verniciabile, dei circuiti conduttori e/o generatori di cariche elettriche e circuiti realizzati con tale procedimento. |
| CA2883641C (en) | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US9956227B2 (en) * | 2013-12-03 | 2018-05-01 | Intra-Cellular Therapies, Inc. | Method for the treatment of residual symptoms of schizophrenia |
| CN113413385A (zh) * | 2014-02-07 | 2021-09-21 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| DK3936130T3 (da) * | 2014-05-06 | 2024-03-25 | Neurocrine Biosciences Inc | Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser |
| JP6919099B2 (ja) * | 2015-06-23 | 2021-08-18 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤 |
| HRP20240304T1 (hr) * | 2015-10-30 | 2024-05-10 | Neurocrine Biosciences, Inc. | Soli valbenazin dihidroklorida i njihovi polimorfi |
-
2017
- 2017-12-01 EP EP24163571.3A patent/EP4400171A3/en active Pending
- 2017-12-01 TW TW106142147A patent/TW201827051A/zh unknown
- 2017-12-01 US US16/465,779 patent/US20200078352A1/en not_active Abandoned
- 2017-12-01 TW TW112107002A patent/TW202345829A/zh unknown
- 2017-12-01 EP EP17817594.9A patent/EP3548027A1/en not_active Withdrawn
- 2017-12-01 WO PCT/US2017/064196 patent/WO2018102673A1/en not_active Ceased
- 2017-12-01 JP JP2019529533A patent/JP2020500875A/ja not_active Withdrawn
- 2017-12-01 TW TW113125691A patent/TW202515564A/zh unknown
-
2020
- 2020-06-03 US US16/891,160 patent/US20210113553A1/en not_active Abandoned
-
2022
- 2022-11-28 JP JP2022189060A patent/JP2023015405A/ja not_active Withdrawn
-
2025
- 2025-01-24 JP JP2025010365A patent/JP2025071099A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500875A5 (cg-RX-API-DMAC7.html) | ||
| JP2016511753A5 (cg-RX-API-DMAC7.html) | ||
| JP2017518334A5 (cg-RX-API-DMAC7.html) | ||
| JP2010270124A5 (cg-RX-API-DMAC7.html) | ||
| PE20141124A1 (es) | Derivados de imidazol fusionados, utiles como inhibidores de ido | |
| JP2018534348A5 (cg-RX-API-DMAC7.html) | ||
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| EP2968372A1 (en) | Minocycline derivatives | |
| JP2016517851A5 (cg-RX-API-DMAC7.html) | ||
| JP2012255026A5 (cg-RX-API-DMAC7.html) | ||
| AR122580A2 (es) | Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| HRP20221495T1 (hr) | Farmaceutske kompozicije koje sadrže derivate imidazotiadiazola i imidazopiridazina kao inhibitore proteazom aktiviranih receptora 4 (par4) za liječenje agregacije trombocita | |
| KR20180021784A (ko) | 피부병의 치료를 위한 니코틴아미드 리보시드 및 프테로스틸벤 조성물 및 방법 | |
| BR112014016788A2 (pt) | composições de ácidos graxos poli-insaturados ômega-3 em forma de ácido livre, enriquecidas com dpa | |
| JP2015509075A5 (cg-RX-API-DMAC7.html) | ||
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| RU2011135417A (ru) | Галеновы препараты органических соединений | |
| CN103717571B8 (zh) | 9‑氨基甲基取代的四环素类化合物 | |
| JP2016510326A5 (cg-RX-API-DMAC7.html) | ||
| MX372770B (es) | Composiciones para comprimidos bucodispersables que contienen corticosteroides para esofagitis eosinofílica. | |
| ME02474B (me) | Terapijski režimi | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2018515463A5 (cg-RX-API-DMAC7.html) |